EASIX as a predictor of 3-year mortality in aortic stenosis patients undergoing TAVR
Clinical Research in Cardiology · 2025-11 · 114 (11) · 1585-1594
DOI: 10.1007/s00392-025-02715-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 23.07.2025. Verfasst von Mustafa Mousa Basha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany. Mustafa.Basha@ukbonn.de. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Bonn.
Abstract (Originalsprache)
Background
Endothelial dysfunction plays a crucial role in the progression of aortic stenosis (AS), and the Endothelial Activation and Stress Index (EASIX) has been proposed as a biomarker for predicting mortality in various clinical settings.
Aims
Evaluating the predictive value of the EASIX for 3-year all-cause mortality in patients undergoing transcatheter aortic valve replacement (TAVR).
Methods
We conducted a retrospective analysis of 1084 patients with severe AS, who underwent TAVR between 2013 and 2021 at the Heart Center Bonn. The EASIX was measured pre-procedural. The optimal cut-off (EASIX ≥ 1.65) was determined using the Youden index. Its association with 3-year mortality was assessed using Kaplan–Meier survival analysis and Cox regression models. The primary endpoint was 3-year all-cause mortality.
Results
Patients with an EASIX ≥ 1.65 had significantly higher 3-year mortality compared to those with lower EASIX (45.8% vs. 27.7%, p < 0.001). In multivariate analysis, EASIX remained an independent predictor of mortality (HR = 1.4, 95% CI: 1.1–1.8, p = 0.010). ROC analysis revealed an area under the curve (AUC) of 63.0% for the EASIX; its predictive ability was inferior to the well-established cardiac biomarkers such as NT-proBNP (AUC = 70.2%) and troponin T (AUC = 69.8%).
Conclusion
The EASIX is a significant predictor of 3-year all-cause mortality in patients undergoing TAVR. However, its predictive performance is lower than NT-proBNP and troponin T. Integrating EASIX with traditional cardiac biomarkers may enhance risk stratification in TAVR patients and improve personalized care. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany. Mustafa.Basha@ukbonn.de.
- Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
- Heart Center Bonn, Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany.
Förderung
- Universitätsklinikum Bonn
Zitieren
APA
Mousa Basha, M., Al-Kassou, B., Gestrich, C., Weber, M., Beiert, T., Zimmer, S., Bakhtiary, F., Nickenig, G., & Shamekhi, J. (2025). EASIX as a predictor of 3-year mortality in aortic stenosis patients undergoing TAVR. Clinical Research in Cardiology, 114(11), 1585-1594. https://doi.org/10.1007/s00392-025-02715-3
Vancouver
Mousa Basha M, Al-Kassou B, Gestrich C, Weber M, Beiert T, Zimmer S, et al. EASIX as a predictor of 3-year mortality in aortic stenosis patients undergoing TAVR. Clinical Research in Cardiology. 2025;114(11):1585-1594. doi:10.1007/s00392-025-02715-3
BibTeX
@article{MousaBasha2025,
author = {Mousa Basha, Mustafa and Al-Kassou, Baravan and Gestrich, Christopher and Weber, Marcel and Beiert, Thomas and Zimmer, Sebastian and Bakhtiary, Farhad and Nickenig, Georg and Shamekhi, Jasmin},
title = {EASIX as a predictor of 3-year mortality in aortic stenosis patients undergoing TAVR},
journal = {Clinical Research in Cardiology},
year = {2025},
volume = {114},
number = {11},
pages = {1585--1594},
doi = {10.1007/s00392-025-02715-3}
}
EUVIMED